TuHURA Biosciences (HURA) Amortization - Deferred Charges (2020 - 2021)
TuHURA Biosciences (HURA) posted quarterly Amortization - Deferred Charges of $20000.0 for Q2 2021, down 13.04% quarter-over-quarter from $23000.0 in Q1 2021.
TuHURA Biosciences (HURA) Amortization - Deferred Charges (2020 - 2021) Analysis & Trends
TuHURA Biosciences' Amortization - Deferred Charges history runs 2 years deep, the most recent figure standing at $20000.0 for Q2 2021.
- In Q2 2021, Amortization - Deferred Charges changed N/A year-over-year to $20000.0; the TTM figure through Jun 2021 stood at $95000.0 (changed N/A YoY), while the FY2021 annual figure was $94000.0, changed N/A from the prior year.
- Amortization - Deferred Charges for Q2 2021 stood at $20000.0, down from $23000.0 in the prior quarter.
- The five-year high for Amortization - Deferred Charges was $27000.0 in Q3 2020, with the low at $20000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 20,000.00 |
| Jun 30, 2021 | 20,000.00 |
| Mar 31, 2021 | 23,000.00 |
| Mar 31, 2021 | 23,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 27,000.00 |
| Sep 30, 2020 | 27,000.00 |